Hamburg speaks out on 'sequestration' affects on FDA; Jazz gets new patent for narcolepsy drug;

 @FiercePharma: Citi says lax cash management costs Big Pharma big bucks. Item | Follow @FiercePharma

> FDA Commissioner Margaret Hamburg expressed concerns as to what automatic budget cuts might mean to the agency if Congress can't span its current deficit reduction impasse. Item

> An FDA reviewer has recommended the agency approve Cornerstone Therapeutics' drug lixivaptan for low sodium levels due to a condition that causes the body to hold excess water, but says the drug should not be approved for heart failure patients, which the company had also sought. Item

> Generic drugmaker Dr. Reddy's Laboratories has launched a generic drug of AstraZeneca's ($AZN) Toprol-XL for treating high blood pressure. Item 

> Spectrum Pharmaceutical has hired former Amgen ($AMGN) exec Ken Keller as its chief operating officer and put him in charge of its pharmaceutical, medical, clinical and commercial operations. Story

Biotech News

 @FierceBiotech: Enzyme deletion slashes Alzheimer's plaque production. Story | Follow @FierceBiotech

 @JohnCFierce: Impressive. Sweden investing $320M in biotech, mostly Stockholm-Uppsala region. Release | Follow @JohnCFierce

 @RyanMFierce: AstraZeneca and Broad team up on discovery of infectious disease drugs. Add to long list of pharma/academia tie-ups. More | Follow @RyanMFierce

> Sweden commits $320M to support ambitious biotech efforts. Article

> FDA review backs Cornerstone's new heart drug - with a hitch. News

> Is there an Alzheimer's Act II in the cards for bapi, solanezumab? More

Medical Device News

 @FierceMedDev: Exagen raised $5.3M for Dx development. News | Follow @FierceMedDev

 @MarkHFierce: As the House looks to IRS implementation of the device tax, AdvaMed continues to fight it. Release | Follow @MarkHFierce

 @DamianFierce: GE touts positive Phase III for its next-gen Alzheimer's imaging agent. Next step: FDA application. More | Follow @DamianFierce

> FDA rejects Navidea's app for cancer diagnostic aid. Story

> Welch Allyn plans to slash 275 jobs, blames device tax. Report

Biotech Research News

> Personalized lung cancer treatments are already out there, researchers conclude. Story

> Respiratory virus tried as targeted cancer treatment. More

> StemCells wins $20M grant to fuel preclinical Alzheimer's treatment advance. Report

> Swedish scientists to test gene therapy for excessively high bone density. Item

Pharma Manufacturing News

> FDA's Woodcock changing up drug quality oversight. Item

> CSL secures U.S. contract to supply flu vaccine antigens. More

> Ipsen keeps up Increlex supply amid Lonza plant failures. Article

> Environmental fights drive China's Harbin to uproot drug factory. Report

And Finally... Jazz Pharmaceuticals says it has secured patent number 10 for its narcolepsy drug, Xyrem. Release

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.